About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
P
IMS 2022 on Updated Results of a Phase 1, First-in-Human Study of ABBV-383, a BCMA × CD3 Bispecific T-Cell Redirecting Antibody, in R/R MM
By
Peter Voorhees
3 Videos
209 views
October 5, 2022
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Related Content
AUTOPLAY
ON
18:26
William Schaffner
Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…
16:42
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…
Feat.
H. Hashmi
19:08
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…
Feat.
R. Banerjee
20:19
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …
Feat.
A. Paulus
12:38
SOHO 2022 Tenth Annual Meeting
SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…
Feat.
S. Usmani
14:09
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…
Feat.
H. Hashmi
49:01
Scripps MD Anderson Cancer Center
Current Summary of the Multiple Myeloma Treatment Landscape
Feat.
R. Lu
12:35
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Treatment Options for Patients With Myelo…
Feat.
C. Cerchione
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
26:46
Samer Al Hadidi
CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…
31:51
Indy Hematology Review
Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…
Feat.
K. Anderson
15:01
Patrick Hagen
Treating High-Risk Pts With Early-Relapsed MM
03:17
Insights from 2023 IMS Annual Meeting
IMS 2023 Insights: "Highlights From the International Myeloma S…
Feat.
J. Richter
20:26
MyCancerHaven
Experts Discuss the Management of Multiple Myeloma at First Relapse
Feat.
R. Vij,
B. Lipe
10:25
Srinivas Devarakonda
Choosing Appropriate Patients for Treatment With Monoclonal Antibody…
07:37
ASH 2022 Conference Coverage
IKEMA Subgroup Analysis: Isatuximab + Carfilzomib & Dexamethason…
Feat.
T. Martin
13:18
Insights from 2023 IMS Annual Meeting
Highlights and Key Takeaways From the 2023 International Myeloma Soc…
Feat.
A. Jakubowiak
21:51
Moffitt Cancer Center
State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? Whe…
Feat.
A. Grajales-Cruz
09:00
Insights from 2023 IMS Annual Meeting
IMS 2023 Insights: "Time to Tailor? Treatment Selection at Firs…
Feat.
M. Delforge
12:33
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Minimizing Uncertainty in Multiple Myelom…
Feat.
K. Patel
